InvestSMART

Percheron Therapeutics Limited (ASX:PER)

ALERT: Price-sensitive ASX Announcement for PER
Current share price for PER : $0.005 -0.003 (-37.50%)+
Announcement
Release
30 Jan 2026 8:46AM
Price at Release
$0.008
Full Release
download
Summary
Percheron Therapeutics Limited has released its Quarterly Activities Report and Appendix 4C Cash Flow Report for the quarter ended 31 December 2025. The report highlights the completion of a phase I clinical trial for HMBD-002, a monoclonal antibody targeting the VISTA checkpoint, showing safety and potential efficacy. The company plans to start a phase II clinical trial in CY2026 with a modular design. The cash flow report shows a cash balance of $4.46 million at the end of the quarter, with net cash outflows of $1.23 million from operating activities, primarily due to R&D expenditures. The company also notes a cash runway of approximately 3.7 quarters under current expenditure levels.
Key Points
  • Completion of phase I clinical trial for HMBD-002.
  • HMBD-002 shows favourable safety and potential efficacy.
  • Plans to commence phase II clinical trial in CY2026.
  • Cash balance of $4.46 million as of 31 December 2025.
  • Net cash outflows from operations totaled $1.23 million.
  • Research and development expenses were significant.
  • Cash runway estimated at 3.7 quarters.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.